Shots:
Brii Bio & VBI Vaccines have signed an asset purchase agreement to acquire IP rights of BRII-179 (novel recombinant protein-based HBV immunotx., expressing Pre-S1, Pre-S2 & S HBV surface antigens)
As per the terms, Brii will acquire BRII-179’s patents, know-how & associated materials for $18M (eliminating all future milestones & royalty obligations). Prior…
